Cat. No.
MABL-3986
Application
IP, therapeutic, WB, ELISA, FC, IF, IHC
Isotype
Engineer antibody
Species Reactivity
Human
Clone No.
J591
From
Recombinant Antibody
Specificity
This antibody binds the extracellular domain of the human PSMA. Prostate-specific membrane antigen (PSMA) is a type II integral membrane glycoprotein belonging to the M28 peptidase family. It acts as a glutamate carboxypeptidase on different alternative substrate. It is highly expressed in cancerous cells and is used as an effective diagnostic and prognostic indicator of prostate cancer.
Alternative Names
PSM; FOLH1; FOLH; FGCP; GCPII; mGCP; NAALAD1; GIG27; Prostate specific membrane antigen; Glutamate carboxypeptidase 2; Cell growth-inhibiting gene 27 protein; Folate hydrolase 1; Folylpoly-gamma-glutamate carboxypeptidase; Glutamate carboxypeptidase II; Membrane glutamate carboxypeptidase; N-acetylated-alpha-linked acidic dipeptidase I; NAALADase I; Prostate-specific membrane antigen; Pteroylpoly-gamma-glutamate carboxypeptidase
UniProt
Q04609
Immunogen
The original antibody was raised by immunizing a mouse with human PMSA. The variable domain regions of mouse J591 were deimmunized by site-directed mutagenesis of putative T-cell reactive epitopes.
Application Notes
This antibody is the de-immunized version of anti-PSMA antibody J591. The radiolabelled version of this antibody was used for a radioimmunoassay on PMSA (US7514078B2). This antibody has been widely used for conjugation with drug maytansinoid 1 (DM1) a microtubule depolymerising agent, through thiopentanoate linker modification method of the antibody. The resulting immunoconjugate (MLN2704) contains 3-4 DM1 molecules per antibody. The immunoconjugate is a chemotherapeutic agent which effectively penetrates xenograft tumor tissue (PMID: 15520207). A phase I trials in patients with progressive, metastatic, castration-resistant prostate cancer investigated the safety profile, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MLN2704. It was observed that the toxicity profile differs substantially from other PSMA-targeted therapies and is more typical of systemic chemotherapy, with nausea, fatigue, and diarrhea being the most commonly encountered adverse effects (PMID: 18362364). In the second study, using the yttrium-90-labeled deJ591-DOTA conjugate, with 61 progressive metastatic CRPC patients, most commonly encountered toxicities were also nausea, fatigue, and schedule-dependent neurotoxicity.
Antibody First Published
Henry et al. A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer. Cancer Res. 2004 Nov 1;64(21):7995-8001. PMID:15520207
Note on publication
Describes the generation of an antibody-drug immunoconjugate which can be used for treatment of prostate cancer.
Size
100 μg Purified antibody.
Concentration
1 mg/ml.
Purification
Protein A affinity purified
Buffer
PBS with 0.02% Proclin 300.
Storage Recommendation
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C.
